All Updates

All Updates

icon
Filter
Earnings/results
Mirati Therapeutics beats analyst estimates in Q2 2023; announces USD 300 million underwritten public offering
Precision Medicine
Aug 8, 2023
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Yesterday
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Yesterday
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Yesterday
Partnerships
Climeworks partners with Terraset to enable philanthropic support for carbon removal
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Funding
8 Rivers secures investment from JX Nippon to commercialize DAC technology
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Sep 17, 2024
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Sep 17, 2024
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Sep 17, 2024
Precision Medicine

Precision Medicine

Aug 8, 2023

Mirati Therapeutics beats analyst estimates in Q2 2023; announces USD 300 million underwritten public offering

Earnings/results

  • Mirati Therapeutics reported a Q2 2023 net loss per share of USD 3.04, beating estimates by 4.1% YoY. The biopharma's net loss rose 0.3% YoY to USD 176.9 million. Net product revenue was USD 13.4 million from the newly launched KRAZATI.

  • Operating expenses increased 10.1% YoY, driven by a 39.3% YoY rise in selling/admin costs from expanded headcount and KRAZATI commercialization. This was partially offset by a 3.2% YoY R&D spending decrease due to reduced sitravatinib clinical costs and lower share-based compensation.

  • Mirati announced an underwritten public offering of 9.7 million shares plus 1.1 million warrant shares, aiming to raise approximately USD 300 million. Net proceeds will fund drug development and leadership expansion and is expected to close on August 12, 2023.

  • The cash, cash equivalents, and short-term investments for June 2023 stood at USD 779.4 million compared to USD 1.1 billion at the end of Q4 2022. The company did not provide guidance for 2023.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.